Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DN5CM6
|
|||
| Drug Name |
Magrolimab
|
|||
| Synonyms |
GS-4721
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 3 | [1] | |
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 3 | [2] | ||
| Company |
Gilead Sciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cell surface glycoprotein CD4 (CD4) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Antigen processing and presentation | ||||
| Hematopoietic cell lineage | ||||
| T cell receptor signaling pathway | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| Pathway Interaction Database | TCR signaling in naï | |||
| IL12-mediated signaling events | ||||
| CXCR4-mediated signaling events | ||||
| C-MYB transcription factor network | ||||
| IL23-mediated signaling events | ||||
| Arf1 pathway | ||||
| Notch-mediated HES/HEY network | ||||
| IL12 signaling mediated by STAT4 | ||||
| Reactome | Binding and entry of HIV virion | |||
| Phosphorylation of CD3 and TCR zeta chains | ||||
| Translocation of ZAP-70 to Immunological synapse | ||||
| Generation of second messenger molecules | ||||
| PD-1 signaling | ||||
| WikiPathways | TCR Signaling Pathway | |||
| Cytokines and Inflammatory Response | ||||
| Host Interactions of HIV factors | ||||
| Defensins | ||||
| HIV Life Cycle | ||||
| TCR signaling | ||||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04778397) Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04313881) Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE). U.S. National Institutes of Health. | |||
| REF 3 | Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.